Puma Biotechnology Inc - Common Stock (PBYI)

Puma (PBYI) Q1 2026 Earnings Call Transcript

Puma Biotechnology (NASDAQ:PBYI) reported first-quarter 2026 total revenue of $44.8 million, driven primarily by NERLYNX product revenue net of $42.0 million and royalty revenue of $2.8 million, according to remarks on the company’s earnings call. Management attributed the quarter’s product revenue

This clinical-stage biotech develops therapies for NASH and obesity, advancing a pipeline of proprietary small-molecule drug candidates.

Puma Biotech (PBYI) Earnings Call Transcript

Puma Biotech's Q3 2025 earnings beat expectations, driven by strong NERLYNX sales. The company raised its full-year revenue guidance and advances its clinical pipeline.

A Delaware jury ordered AstraZeneca to pay Pfizer $107.5 million, ruling that AstraZeneca's lung cancer drug Tagrisso infringed on Pfizer's patents related to cancer treatment.

PBYI stock results show that Puma Biotechnology beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024.

Discover seven promising stocks priced under $15, leading in sectors like financial services, biotechnology, and energy.

Companies Reporting Before The Bell • Frontline (NYSE:FRO) is expected to report quarterly earnings at $0.46 per share on revenue of $276.19 million.

Companies Reporting Before The Bell • Cedar Fair (NYSE:FUN) is likely to report quarterly earnings at $1.10 per share on revenue of $512.74 million.

A strong buy rating carries weight which speculative investors may want to research in these strong buy stocks under $5.